|
 |
| home > epc > winter 2001 > the trojan horse of oncology - the role of stealth drug delivery |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
The word 'cancer' instils fear into most people. One in four people will develop cancer at some point in their life and, given the dismal cure rates for most common cancers, many of those who are diagnosed with some form of the disease will eventually die of it. Fear is often augmented by the knowledge that the relentlessly growing cancer often brings with it pain, suffering and debility.
Far from being 'mindless' automatons, it has been shown that tumour cells employ numerous strategies to promote growth. Complicated mechanisms to switch on growth; vascular endothelial growth factors (VEGF) to create a blood supply as a pipeline to bring nutrients; and pumps such as p-Glycoprotein to get rid of ingested cellular toxins are some of the strategies that have evolved.
While the fight against cancer begins with prevention, once it has developed, permanent eradication of the disease requires all the skills oncologists can muster to outwit the tumour cell and the mechanisms it employs to ensure its continued cellular survival and tumour growth.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
3rd Annual Clinical Trial Management Systems (CTMS)
18-19 March 2010, Philadelphia, PA, US
Pharmaceutical and biotech companies are increasingly looking to clinical trial management systems (CTMS) to help streamline their clinical development operations. Building on a successful two-year history, this programme continues to serve as an excellent platform for industry discussion and collaboration among various CTMS stakeholders. This programme addresses the challenges of integrating CTMS systems both within the organisation across various other clinical systems as well as with external systems. Don’t miss this opportunity to hear in-depth industry case studies and learn from the challenges and successes of other companies.
More info >> |
|
 |
News and Press Releases |
 |
BAC Extends Partnership with GE Healthcare to Launch Alpha-1 Antitrypsin Select
BAC BV, the leading provider of antibody-based affinity purification technology, has extended its collaboration with GE Healthcare with the addition of a new bioprocess affinity chromatography ligand to GE Healthcare’s range of custom designed media. The latest addition to the range is an affinity resin for the purification of alpha-1 antitrypsin (AAT) from blood plasma, recombinant cell culture or transgenic sources. The new resin has been developed as part of GE Healthcare’s Custom Designed Media (CDM) programme and provides a new solution for AAT purification in the biopharmaceutical industry.
More info >> |
|
 |
